Jasmeet Kaur
Roswell Park Cancer Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jasmeet Kaur as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:37 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06202066 · Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine CarcinomasRoswell Park Cancer Institute · not yet recruiting · Digestive System Neuroendocrine Neoplasm, Lung Neuroendocrine Neoplasm, Malignant Solid Neoplasm · principal investigator
- Ph1NCT03879694 · Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine TumorsRoswell Park Cancer Institute · completed · Lung Atypical Carcinoid Tumor, Lung Typical Carcinoid Tumor, Metastatic Pancreatic Neuroendocrine Tumor · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:37 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in pancreatic cancer.